Stifel Nicolaus Cuts Nkarta (NASDAQ:NKTX) Price Target to $14.00

Nkarta (NASDAQ:NKTX) had its price objective reduced by Stifel Nicolaus from $15.00 to $14.00 in a research report sent to investors on Thursday,Benzinga reports. They currently have a buy rating on the stock.

NKTX has been the topic of several other research reports. HC Wainwright reaffirmed a “buy” rating and set a $18.00 target price on shares of Nkarta in a research report on Thursday. Needham & Company LLC reaffirmed a “buy” rating and set a $11.00 price objective on shares of Nkarta in a research report on Thursday. Six analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $14.86.

Nkarta Trading Up 1.5 %

Shares of Nkarta stock opened at $2.00 on Thursday. The stock’s fifty day moving average price is $1.99 and its 200-day moving average price is $2.84. The firm has a market cap of $141.92 million, a P/E ratio of -1.06 and a beta of 0.90. Nkarta has a 12 month low of $1.31 and a 12 month high of $11.84.

Nkarta (NASDAQ:NKTX) last posted its quarterly earnings results on Wednesday, March 26th. The company reported ($0.35) EPS for the quarter, beating the consensus estimate of ($0.41) by $0.06. Analysts forecast that Nkarta will post -1.7 earnings per share for the current year.

Insider Activity at Nkarta

In other Nkarta news, CEO Paul J. Hastings sold 17,378 shares of the business’s stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $2.20, for a total transaction of $38,231.60. Following the sale, the chief executive officer now owns 319,859 shares of the company’s stock, valued at approximately $703,689.80. The trade was a 5.15 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 8.70% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Nkarta

Several institutional investors and hedge funds have recently made changes to their positions in NKTX. Intech Investment Management LLC acquired a new stake in Nkarta during the 3rd quarter worth about $74,000. FMR LLC lifted its holdings in shares of Nkarta by 97.1% during the third quarter. FMR LLC now owns 133,149 shares of the company’s stock worth $602,000 after purchasing an additional 65,600 shares during the period. Wasatch Advisors LP boosted its position in Nkarta by 31.7% in the third quarter. Wasatch Advisors LP now owns 1,834,680 shares of the company’s stock valued at $8,293,000 after buying an additional 442,125 shares during the last quarter. Erste Asset Management GmbH acquired a new position in Nkarta in the 3rd quarter worth approximately $33,000. Finally, State Street Corp lifted its stake in Nkarta by 1.4% during the 3rd quarter. State Street Corp now owns 1,098,062 shares of the company’s stock valued at $4,963,000 after acquiring an additional 15,569 shares during the period. 80.54% of the stock is currently owned by institutional investors and hedge funds.

About Nkarta

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.